We back extraordinary founders turning scientific research into products addressing the world’s greatest challenges.
Our investments
We partner with transformative companies from Oxford University and other world-leading UK research institutions.
Professor Antoniades is transforming how cardiovascular risk is understood and detected.
His discovery of the Fat Attenuation Index (FAI) biomarker enables the detection of cardiac inflammation through standard heart scans – redefining early diagnosis and prevention.
Professor Charalambos Antoniades
Co-founder & Chief Scientific Officer
Caristo Diagnostics
Dr Leek is building quantum computers, already integrated in data centres in London, Japan and New York.
OQC’s core technology originates from his research group at the University of Oxford, which he has led since 2012.
Dr Peter Leek
Founder & Chief Scientific Officer
Oxford Quantum Circuits
Professor Coussios pioneered technology that keeps donor organs viable outside the body – dramatically improving transplant outcomes and saving lives.
OrganOx has become a global leader in organ preservation technology worldwide, culminating in a successful $1.5bn exit to Terumo in 2025.
Professor Constantin Coussios
Co-founder
OrganOx
Discover OTIF
Breakthrough technologies are born in universities - home to some of the world’s brightest minds.
We believe deep integration within university spinout ecosystems compounds knowledge, access and long-term investment outcomes.
Founded in 2015, we invest in companies from Seed and follow-on through to Exit.
Over 150 investments in university deep-science spinouts – with proven exits.
OTIF provides sophisticated investors with access to high-potential university spinouts.
We focus on long-term capital growth and portfolio diversification, targeting enhanced risk-adjusted returns through a tax-efficient EIS structure.
Investments span early-stage investments and select de-risked growth opportunities.
We are a team of founders, investors and scientists with specialist spinout experience.
Beyond capital, we actively support our portfolio – serving as board representatives and strategic partners to help maximise value creation.
Our sectors
Life Sciences
Advancing breakthroughs in therapeutics, medical devices and life science tools that improve outcomes and extend lives.
Deep Tech
Backing frontier technologies across quantum computing, AI, and advanced hardware, solving complex challenges with defensible, scalable solutions.
Physical Sciences
Translating fundamental scientific discoveries into real-world applications across materials, energy, and advanced manufacturing.